Arbutus Biopharma (ABUS) Current Leases (2019 - 2026)
Arbutus Biopharma (ABUS) posted Current Leases of $631000.0 for Q1 2026, up 15.36% sequentially from $547000.0 in Q4 2025, and up 12.08% YoY from $563000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Current Leases (2019 - 2026) Analysis & Trends
Arbutus Biopharma has reported Current Leases for 8 years, with the latest figure at $631000.0 in Q1 2026.
- Quarterly Current Leases rose 12.08% year-over-year to $631000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $631000.0 (up 12.08% YoY) and the FY2025 annual result came in at $547000.0, up 13.25% from the prior year.
- Current Leases grew to $631000.0 in Q1 2026 per ABUS's latest filing, from $547000.0 in the prior quarter.
- Over five years, Current Leases peaked at $631000.0 in Q1 2026 and troughed at $360000.0 in Q3 2022.
- A 5-year average of $465882.4 and a median of $453000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2023: Current Leases slipped 6.74% in 2022, then gained 14.44% in 2023.
- Over 5 years, Current Leases stood at $372000.0 in 2022, then increased by 14.25% to $425000.0 in 2023, then advanced by 13.65% to $483000.0 in 2024, then increased by 13.25% to $547000.0 in 2025, then increased by 15.36% to $631000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $631000.0, $547000.0, and $531000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 514,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 514,000.00 |
| Mar 31, 2026 | 631,000.00 |
| Dec 31, 2025 | 547,000.00 |
| Sep 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 514,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Sep 30, 2024 | 468,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 502,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Sep 30, 2023 | 412,000.00 |
| Jun 30, 2023 | 397,000.00 |
| Mar 31, 2023 | 446,000.00 |
| Dec 31, 2022 | 372,000.00 |
| Sep 30, 2022 | 360,000.00 |
| Jun 30, 2022 | 377,000.00 |
| Mar 31, 2022 | 439,000.00 |
| Dec 31, 2021 | 383,000.00 |
| Sep 30, 2021 | 386,000.00 |